Skip to main content
. 2021 Feb 22;10:573801. doi: 10.3389/fonc.2020.573801

Table 3.

Network meta‐analysis of PFS in HRD positive patients.

Niraparib
1.2 (0.70, 2.0) Rucaparib
0.38 (0.24, 0.60) 0.32 (0.24, 0.42) Placebo

Results in each cell represent the pooled HR and its 95% CrI. The estimates are located at the crossing between the column‐defining treatment and row‐defining treatment. An HR lower than one favors the column‐defining treatment. The significant results are presented in bold.